Hikma Pharmaceuticals (HKMPF) Receives Consensus Rating of “Hold” from Brokerages

Shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) have received an average rating of “Hold” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company.

A number of research analysts have recently commented on HKMPF shares. Jefferies Group downgraded Hikma Pharmaceuticals from a “hold” rating to an “underperform” rating in a research report on Wednesday, January 10th. ValuEngine upgraded Hikma Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Finally, Zacks Investment Research upgraded Hikma Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th.

HKMPF remained flat at $$17.10 during trading on Tuesday. Hikma Pharmaceuticals has a 52 week low of $12.00 and a 52 week high of $25.35.

COPYRIGHT VIOLATION NOTICE: “Hikma Pharmaceuticals (HKMPF) Receives Consensus Rating of “Hold” from Brokerages” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3341591/hikma-pharmaceuticals-hkmpf-receives-consensus-rating-of-hold-from-brokerages.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Investors Buy Shares of 3M  on Weakness
Investors Buy Shares of 3M on Weakness
Investors Buy Shares of Caterpillar  on Weakness
Investors Buy Shares of Caterpillar on Weakness
Inseego  Downgraded by ValuEngine
Inseego Downgraded by ValuEngine
ValuEngine Lowers Habit Restaurants  to Strong Sell
ValuEngine Lowers Habit Restaurants to Strong Sell
Community Trust Bancorp  Upgraded to Buy at ValuEngine
Community Trust Bancorp Upgraded to Buy at ValuEngine
QUALCOMM  Earns Hold Rating from Stifel Nicolaus
QUALCOMM Earns Hold Rating from Stifel Nicolaus


Leave a Reply

© 2006-2018 Ticker Report. Google+.